Keywords: Tumors (Post-Treatment), Perfusion, brain tumor, DSC-MRI
Motivation: Tumor treating fields (TTFields) is a novel treatment modality for patients with newly diagnosed and recurrent glioblastoma (GBM). How to best monitor response to TTFields remains unclear with conventional MRI shown to be unreliable.
Goal(s): Fractional tumor burden (FTB) maps, derived from DSC-MRI perfusion imaging, were evaluated for this purpose.
Approach: Conventional and perfusion MRI data were collected before and up to 6 months after TTField treatment. Changes in conventional and FTB metrics were evaluated for their ability to predict outcomes.
Results: Change in FTB at 1-2 months post treatment initiation provide an early indicator of response to TTFields.
Impact: Use of perfusion-derived fractional tumor burden (FTB), as an early indicator of response to Tumor Treating Fields, overcomes current limitations with conventional MRI that should substantially alter how these patients are managed.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords